Circadian Phase in Chronic Insomnia by Pfahl, Jamie
University of Colorado, Boulder
CU Scholar
Undergraduate Honors Theses Honors Program
Spring 2011
Circadian Phase in Chronic Insomnia
Jamie Pfahl
University of Colorado Boulder
Follow this and additional works at: http://scholar.colorado.edu/honr_theses
This Thesis is brought to you for free and open access by Honors Program at CU Scholar. It has been accepted for inclusion in Undergraduate Honors
Theses by an authorized administrator of CU Scholar. For more information, please contact cuscholaradmin@colorado.edu.
Recommended Citation
Pfahl, Jamie, "Circadian Phase in Chronic Insomnia" (2011). Undergraduate Honors Theses. Paper 617.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Circadian Phase in Chronic Insomnia 
 
 
 
Jamie Pfahl 
 
 
 
An Honors Thesis 
 
Submitted to the Department of Integrative Physiology 
College of Arts and Sciences of the University of Colorado 
 
 
 
3/31/2011 
 
 
 
 
 
 
Committee 
 
Kenneth P. Wright Jr., Ph.D., Advisor, Department of Integrative Physiology 
 
Albert Kim, Ph.D., Department of Psychology and Neuroscience 
 
David E. Sherwood, Ph.D., Honors Council Member 
 
 
1 
 
 
Table of Contents 
Abstract.........................................................................................................................................................2 
Introduction..................................................................................................................................................3 
Insomnia.....................................................................................................................................................4 
Treatments for Insomnia ............................................................................................................................5 
Background ..................................................................................................................................................8 
Homeostatic sleep drive and circadian rhythm..........................................................................................8 
Chronotypes: owls and larks ......................................................................................................................9 
Entrainment..............................................................................................................................................10 
SCN..........................................................................................................................................................11 
Constant Routine......................................................................................................................................12  
Delayed and advanced sleep phase syndrome .........................................................................................14 
Current Study ............................................................................................................................................16 
Aims, hypotheses .....................................................................................................................................16 
Methods....................................................................................................................................................17 
Results......................................................................................................................................................18 
Discussion ................................................................................................................................................21  
Appendix .....................................................................................................................................................24  
References ...................................................................................................................................................25 
 
 
2 
 
 
ABSTRACT 
Introduction:  
Melatonin and melatonin agonists like ramelteon have been shown to be successful at treating 
insomnia without the significant side effects and withdrawal effects of the sedatives and 
hypnotics that are traditionally prescribed for this condition.  Furthermore, traditional 
pharmacological treatments for insomnia do not address the underlying physiological, 
psychological, and behavioral causes of insomnia.  When combined with behavioral therapy, 
treatments for insomnia are more effective and longer lasting.  In addition, some types of 
insomnia are connected with circadian misalignment with the external environment.  Melatonin 
and melatonin agonists may treat these types of insomnia by adjusting circadian phase.  The aim 
of this thesis was to compare the change in circadian phase, as determined by salivary melatonin 
levels, from pre- and post-treatment with 8mg of ramelteon combined with multi-component 
behavioral therapy (MCBT) or with ramelteon alone compared to placebo in chronic insomniacs.  
The hypothesis of this thesis is that there will be a greater change in circadian phase with 
ramelteon and MCBT than in the placebo group.  We expect that a change in circadian phase will 
be correlated with improvement in subjective sleep quality. 
 
Methods:  
Thirty one adults aged 18-64 that met the criteria for chronic insomnia (sleep onset latency of 
more than 30 minutes on at least 3 nights a week and average total sleep time less than 6.5 hours) 
were studied at the University of Arizona under the supervision of Dr. Richard Bootzin.  
Subjects received either 8mg ramelteon or placebo daily in combination with MCBT.  Subjects 
in the MCBT/ramelteon condition received weekly therapy sessions in addition to the drug.  
Sleep diaries and subjective sleep measures were recorded throughout the treatment period.  
Saliva samples were taken under dim light conditions (<25 lux) every hour during pre and post-
treatment visits to assess circadian phase. Frozen saliva samples were shipped to the University 
of Colorado where they were assayed using a high sensitivity ALPCO ELISA kit.  DLMO was 
determined using a 3pg/mL threshold and the change in circadian phase was calculated by 
comparing the difference between pre- and post- treatment bedtimes and DLMO. 
 
Results:   
A significant (p<.05) change in phase angle was found between the ramelteon-only group and 
placebo.  Significant improvements in subjective measures were seen in all groups.  There was 
no association between change in phase angle and treatment efficacy. 
  
Conclusion:  
Our findings further support existing evidence that a standard 8mg dose of ramelteon can 
effectively shift the circadian clock so that individuals sleep at a more appropriate biological 
time.  Although we did not find that a change in phase angle was associated with treatment 
efficacy, ramelteon alone or in combination with MCBT continues to show promise in the 
treatment of insomnia.  However, further research needs to be done to verify and test the scope 
of these results. 
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INTRODUCTION 
 
Although most humans spend about one third of their lives sleeping, scientists in the field 
of sleep medicine are still just beginning to grasp the scope and complexity of how sleep and 
circadian rhythms interact with other biological processes such as hormone secretion, 
metabolism, and learning and development.  Through this research, adequate sleep and proper 
circadian alignment has proven to play a critical role in health and well-being in various areas of 
medicine.  For example, recent studies implicating inadequate sleep in the etiology of obesity, 
diabetes, and cardiovascular disease underscore the importance of the field of sleep in modern 
medicine as the incidence of these diseases rises (Scheer, Hilton et al. 2009; Cardinali, Cano et 
al. 2011).   Sleep disorders can have far-reaching consequences, from hormonal and metabolic 
imbalances to fatigue that results in workplace or motor vehicle accidents.  A 2004 study in 
Australia calculated the approximate costs of sleep disorders to be 7.5 billion USD across a 
population of 20.1 million, out of whom less than 10% were estimated to suffer from a chronic 
primary sleep disorder (Hillman, Murphy et al. 2006).  Although insomnia was only estimated to 
affect 5% of the Australian population, this cost analysis included an estimated $8.8 million 
spent on pharmaceuticals to help induce and maintain sleep. Furthermore, 76% of the drugs 
prescribed were hypnotics, which have been shown to increase the risk of motor vehicle 
accidents (Gustavsen, Bramness et al. 2008).  The injuries and property damage resulting from 
the drugs used to treat sleep disorders further add to the indirect costs of these disorders.  It is 
clear that the physiological effects and economic costs of sleep disorders are far-reaching, and 
more needs to be done to ensure that treatments are easily available, low-risk, and effective. 
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Insomnia 
 Insomnia, broadly defined as difficulty initiating or maintaining sleep that results in 
sleep of poor duration and quality1, is reported to affect anywhere between 4-50% of the 
population (Wade 2010).  Because of the broad use of the term “insomnia” among the general 
public, more stringent clinical criteria (such as the presence of daytime impairment) are typically 
used to obtain closer estimates, which fall around 10% (Roth, Krystal et al. 2007).  To further 
complicate this matter, insomnia often appears in conjunction with other disorders like 
depression and anxiety, potentially spurning a vicious cycle of anxiousness, frustration, and poor 
sleep.  Figure 1 shows the results from a 1998 study in France that described some of the 
complexities in the interactions between depressive and anxiety disorders with insomnia 
(Ohayon, Caulet et al. 1998).  The data in Figure 1 is from the 17.7% of the studied population 
who fit the criteria listed in the DSM-IV2 to further classify insomnia into these six categories.  
Over half of those interviewed who met the criteria for insomnia also experienced depression or 
anxiety symptoms.  In cases like these, it can be difficult to 
discern the causal relationship – if any – between insomnia 
and these disorders, which makes it difficult both to study 
and to treat (Simon and VonKorff 1997).   
 
 
 
 
                                                
1 Poor sleep can be measured subjectively (ie. not feeling refreshed, feeling like one spent the night tossing and 
turning) or objectively, with measures like sleep onset latency (SOL), total sleep time (TST), EEG parameters, etc. 
2 The DSM-IV (Diagnostic and Statistical Manual) is published by the American Psychiatric Association and 
includes descriptions and classifications of mental disorders. 
Figure 1.  Distribution of insomnia 
by diagnostic category 
Primary Insomnia 7.3% 
Insomnia related to a 
depressive disorder 
8.1% 
Insomnia related to an 
anxiety disorder 
8.4% 
Depressive disorder with 
insomnia symptoms 
10% 
Anxiety disorder with 
insomnia symptoms 
37.7% 
Isolated insomnia 
symptoms 
28.4% 
(Ohayon, Caulet et al. 1998) 
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Treatments for insomnia 
Because there are different types of insomnia with different causes and comorbidities3, 
there are a variety of psychological, pharmacological, and behavioral treatments that can be 
implemented to treat insomnia and its symptoms.  However, not all of these treatments are 
equally sought or prescribed.  One study revealed that nearly one third of insomniacs use 
psychotropic medications but only 13% sought mental health services.  Of those who utilized 
mental health services, 36% had comorbid depression and only 5% were seeking treatment for 
insomnia alone (Simon and VonKorff 1997).  This indicates that insomnia is often treated as a 
symptom, not as an independent disorder which often has its own underlying cause.  More 
surprising is the overwhelming use of psychotropic drugs, given that they must be taken 
continually, and sleep problems tend to re-emerge upon discontinuance.   In one two-year study, 
only 22% of those with severe insomnia who were taking hypnotics reported significant 
improvements in their sleep (Hohagen, Rink et al. 1993). 
The most commonly prescribed sleep drugs are hypnotics such as the non-
benzodiazepines Ambien and Lunesta, which are GABAA receptor agonists.  GABA, the brain’s 
primary inhibitory neurotransmitter, promotes sleep by causing wide-spread inhibition across the 
wakefulness-promoting regions in the cerebral cortex, thalamus, and hypothalamus (Gottesmann 
2002; Szabadi 2006). Both benzodiazepines and non-benzodiazepines cause this general central 
nervous system depression, and may have serious side-effects including daytime impairment, 
rebound effects after discontinuing use, and potential for abuse (Szabadi 2006).  These drugs 
have also been shown to alter sleep architecture4, usually causing an increase in stage 2 sleep and 
a decrease in slow wave activity (Parrino and Terzano 1996).  
                                                
3 Comorbidity is the medical term for when one or more diseases or disorders occur together. 
4 Sleep architecture refers to the EEG measure of how sleep is distributed across sleep stages throughout the night. 
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To avoid the next-day “hangover effect” resulting from the use of drugs that act on the 
GABAergic system, scientists have recently invested in exploring the use of melatonin and 
melatonin agonists to improve sleep in insomniacs and healthy sleepers.  Melatonin is a naturally 
occurring hormone that is secreted by the pineal gland and plays an important role in the 
circadian regulation of the sleep/wake cycle.  The synthesis and release of melatonin from the 
pineal gland is almost entirely inhibited during the day by the suprachiasmatic nucleus (SCN) of 
the anterior hypothalamus.  The SCN receives information about environmental light conditions 
from the retina, and passes this information on through its projections to other brain areas, which 
are summarized later in this paper in Figure 2.  When the SCN’s inhibition of the pineal gland is 
removed, circulating melatonin levels rise and feed back to the SCN (Moore 1997).  The sleep-
promoting functions of melatonin are facilitated through its actions on the MT1 and MT2 
receptors that are located throughout the body but primarily in the SCN (Pandi-Perumal, 
Srinivasan et al. 2007; Pandi-Perumal, Srinivasan et al. 2009).      Because melatonin works 
independently of the GABA system, it does not result in the general central nervous system 
depression that causes morning impairment and other unwanted side effects (Roth, Stubbs et al. 
2005; van den Heuvel, Ferguson et al. 2005).   
 Melatonin has been successfully used in the treatment of insomnia in older individuals 
and shows promise as a safe and effective alternative to sedative or hypnotic drugs (Haimov, 
Lavie et al. 1995; Zhdanova, Wurtman et al. 2001; Leger, Laudon et al. 2004).  Not all studies, 
however, demonstrate a significant effect of melatonin on improving sleep.  While most studies 
find that melatonin significantly decreases sleep onset latency (SOL)5, others conclude that the 
effects of melatonin are not strong enough to promote and maintain sleep in all populations (van 
den Heuvel, Ferguson et al. 2005).  For example, since melatonin does not cause an involuntary 
                                                
5 Sleep latency is a measure of how long it takes someone to fall asleep while lying in bed. 
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loss of consciousness even at very high doses, its effects can be modified by an individual’s 
desire to stay alert (ie. it is easy to make the decision to stay up past one’s bedtime) (van den 
Heuvel, Ferguson et al. 2005).  Melatonin’s short half-life of approximately 20 minutes in blood 
and the variability of effect depending on time of administration have also been implicated as 
limits to its use as a sleep aid (van den Heuvel, Ferguson et al. 2005; Pandi-Perumal, Srinivasan 
et al. 2007) .   
Because melatonin has not been proven as an effective sleep aid in all cases, 
pharmaceutical companies are now exploring synthetic drugs that act similarly to melatonin. One 
melatonin agonist in particular, ramelteon, has been shown to reduce SOL and improve total 
sleep time (TST) (Roth, Stubbs et al. 2005).  Ramelteon binds specifically to melatonin receptors 
with a higher affinity than melatonin and has a longer half-life, which could help enhance and 
prolong its sleep-promoting effects (Pandi-Perumal, Srinivasan et al. 2007). 
In addition to pharmacological interventions, behavioral therapies have been shown to 
help improve sleep in insomniacs.  The type of therapy used in this study, Multi-Component 
Behavioral Therapy (MCBT), consists of different modules (stimulus control instructions, sleep 
restriction therapy, sleep education, and cognitive therapy) which address different factors that 
may contribute to poor sleep.  Variations of these therapeutic tools have been applied in 
numerous studies, and overall results conclude that cognitive behavioral therapies achieve 
positive results in both subjective and objective measures of sleep quality including improving 
TST, reducing wakefulness after sleep onset (WASO), and reducing SOL  (Morin, Bootzin et al. 
2006).  These treatments can also help reduce the dosages of sleep medications being used by 
insomniacs and the effects tend to persist for months after discontinuing treatment (Morin, 
Bootzin et al. 2006).  Among the types of therapy that were found to be particularly effective 
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treatments for insomnia include stimulus control therapy, sleep restriction, and cognitive 
behavioral therapy, which are three of the four components of MCBT (Morin, Bootzin et al. 
2006).   More information on the components of MCBT can be found in the Appendix. 
 
BACKGROUND 
 
In healthy individuals sleep and circadian rhythms are timed so that brain functions, 
physiological processes, and behaviors occur at optimal environmental times corresponding with 
the light-dark cycle and its changes across the year.  These rhythms can even be observed in 
organisms as simple as cyanobacteria and molds, playing an important role in both biochemical 
and behavioral aspects of life across all species from seasonal reproductive cues to memory 
formation (Gillette and Tischkau 1999).  
Homeostatic sleep drive and circadian rhythm 
In humans and many other species, daily patterns of sleep and wakefulness are the result 
of interactions between the homeostatic drive for sleep and the circadian rhythm in what is 
known as the two-process model of sleep regulation (Borbely and Achermann 1999).   
Homeostatic sleep drive, known as Process S, increases across the day and dissipates during 
sleep.  With prolonged wakefulness, brain glycogen6 levels decrease as the brain uses its energy 
stores, but are restored after sufficient recovery sleep (Kong, Shepel et al. 2002).  In addition to 
decreased brain glycogen levels with prolonged wakefulness, adenosine7 accumulates in the 
brain, which may act as a signal to activate the brain’s sleep-promoting centers (Saper, Scammell 
et al. 2005).  These biochemical changes in the brain are proposed to be mechanisms by which 
                                                
6 Glycogen is the storage form of glucose, the brain’s primary source of energy. 
7 Adenosine is a metabolic by-product resulting from the breakdown of ATP for energy. 
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the homeostatic sleep drive promotes sleep to occur.  These homeostatic signals continuously 
interface with the circadian rhythm, or Process C, which is a near 24-hour endogenously driven 
rhythm controlled by the SCN.  Process C promotes wakefulness over the course of the day to 
counteract the increasing homeostatic sleep drive, thereby maintaining wakefulness.  During the 
biological night, and under control of the circadian system, the pineal hormone melatonin is 
synthesized and released into the blood as described previously.  Melatonin levels typically rise 
around 2 hours prior to habitual bedtime, and decline shortly before waking (Wright, Gronfier et 
al. 2005).  Sleep is initiated after the circadian peak, where the homeostatic and circadian 
systems are both promoting sleep.  This zone of high propensity for sleep corresponds with a 
decrease in cognitive performance because of the strong drive for sleep being enforced by both 
the homeostatic and circadian processes at this time (Wright, Hull et al. 2002; Rogers, Dorrian et 
al. 2003).	  
Chronotypes – owls and larks 
The period (τ) of the circadian rhythm varies between individuals and typically falls 
within 1 hour of the 24 hour earth day, with an average of ~24.2 hours (Duffy and Wright 2005). 
In one 1999 study, the intrinsic circadian period of 11 young adult men and 13 older adults was 
assessed over a month-long forced desynchrony protocol8.  The researchers found a standard 
distribution of periods ranging from 23.9 to 24.5 hours with the peak at 24.2 hours (Czeisler, 
Duffy et al. 1999).  While this group of researchers found no difference in circadian period 
between older and younger subjects, they did report that the older subjects studied did have 
earlier entrained circadian rhythms and early morning awakening that is typical in the elderly 
(Duffy, Dijk et al. 1998; Czeisler, Duffy et al. 1999).   
                                                
8 In a forced desynchrony protocol, subjects are kept in dim-light conditions with a scheduled sleep/wake cycle that 
is several hours shorter or longer than the 24 hour day (ie. 28 hours), which desynchronizes the sleep wake cycle 
from the endogenous circadian rhythm. 
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At the extremes of the circadian spectrum are morning and evening-types, known 
colloquially as “larks” and “owls”.   These chronotypes express significant differences in 
alertness and cognitive performance across the day with morning-types being more alert and 
having better performance on cognitive tasks earlier in the day than their evening-type 
counterparts (Horne, Brass et al. 1980).  However, alertness and cognitive performance are also 
closely tied to the sleep/wake cycle.  A 2003 study suggests that the contributions of homeostatic 
and circadian processes to sleep pressure differ between morning and evening types (Taillard, 
Philip et al. 2003).  The differences in circadian and homeostatic interactions between 
chronotypes has implications for the effects of people sleeping outside their optimal circadian 
time, as occurs in some types of insomnia. 
Entrainment 
Despite differences in τ, most individuals are able to synchronize their circadian rhythm 
to periodic cues from the external environment and maintain a very tight distribution around the 
24-hour earth day.  Entrainment is said to occur when the internal clock is synchronized with 
environmental time cues, known as zeitgebers9 (Lack and Wright 2007).   For humans, light is 
the primary zeitgeber, which coordinates sleep and wake activity with the alternating periods of 
environmental darkness and light (Wehr, Aeschbach et al. 2001).   As most individuals have 
innate circadian periods slightly longer or shorter than the 24 hour earth day, they must entrain 
themselves daily to maintain synchrony between their internal clock and environmental time.   A 
2005 study revealed that for healthy individuals, an adjustment of only 10-15 minutes is needed 
to re-entrain the circadian clock to the external environment each day depending on the 
individual’s circadian period (Czeisler, Duffy et al. 1999).   Individuals with a period shorter 
                                                
9 Zeitgeber – German for “time giver” (Lack and Wright 2007). 
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than 24 hours require a daily phase delay, while those with a longer period must undergo a daily 
phase advance in order to re-synchronize their biological clock to the 24-hour day.   
The relationship between biological time and environmental time is known as the phase 
angle of entrainment (Duffy and Wright 2005).  The phase angle of entrainment can be described 
by any circadian marker (ie. dim light melatonin onset or core body temperature minimum), 
relative to environmental or physiological events (ie. habitual sleep time). 
The SCN 
The SCN, located in the anterior hypothalamus, is known as the “master clock”.  The 
SCN acts as a synchronizer for other “clocks” located peripherally throughout the entire body 
(Dibner, Schibler et al. 2010).  The position of the SCN in the hypothalamus is biologically 
convenient for the transmittance of photic cues from the environment as it is positioned just 
above the optic chiasm and receives light cues from the retina through the retinohypothalamic 
tract (Dibner, Schibler et al. 2010).  These input signals are critical to the entrainment of the 
circadian clock, and are found to be most effective at shifting the clock when they occur during 
specific phases of the circadian cycle.  For example, in a normally entrained individual, light 
received at night is perceived as an error to which the biological clock must adjust (Gillette and 
Tischkau 1999).  These periods of sensitivity to the phase resetting effects of light have 
implications for the treatment of circadian disorders with light therapy, as described later in this 
paper.  
The SCN projects to other hypothalamic areas to synchronize processes throughout the 
body, as shown in Figure 2 below (Moore 1997).  Synchronization of these processes can occur 
indirectly via body temperature rhythms or feeding and activity rhythms controlled by the 
hypothalamus, or directly via humoral and neural signals from the SCN (Dibner, Schibler et al. 
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2010).  For example, neuronal firing rate and vasopressin secretion are two primary SCN output 
signals that oscillate across the circadian cycle and provide information about the passage of time 
and the phase of the clock (Gillette and Tischkau 1999).  
 
 
 
 
 
 
Constant Routine 
In humans, SCN output rhythms such as core body temperature (CBT) and melatonin are 
used to infer the status of the biological clock.  However, these rhythms are sensitive to 
environmental and behavioral factors such as external temperature, food intake, light exposure, 
physical activity, and even posture, and therefore must be studied under very controlled 
conditions.  For example, when a person stands up, gravity immediately causes blood to pool in 
the lower extremities, which in turn causes plasma fluid to leak into the surrounding tissues.  
This has been shown to raise the concentration of plasma components, particularly proteins 
(which melatonin is usually bound to), by 10-20% (Deacon and Arendt 1994).  Because salivary 
melatonin levels closely reflect levels circulating in the blood, it is important to control for 
posture regardless of sampling plasma or saliva to measure the melatonin rhythm (Nagtegaal, 
Peeters et al. 1998).  
Light is another factor that must be controlled for when assessing circadian phase, as it is 
the most potent zeitgeber for the mammalian circadian clock (Roenneberg and Foster 1997).  
SCN 
BASAL FOREBRAIN 
THALAMUS 
HYPOTHALAMUS 
Attention, memory, sensorimotor integration, emotion 
Endocrine regulation, metabolism, body temperature,  
sleep-wake cycles, melatonin 
Figure 2. SCN projections within the brain and some the functions they regulate.  The circadian rhythm is primarily 
regulated by secondary projections from the hypothalamus to the anterior pituitary, reticular formation, and pineal 
gland. 
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The timing, intensity, and wavelength of light are all important factors in entrainment, as the 
sleep-promoting hormone melatonin is acutely suppressed by light, and the degree of melatonin 
suppression is correlated with the intensity, timing, and duration of light exposure.  Wavelengths 
in the blue-green area of the visible spectrum (470-525nm) have been shown to be most effective 
at suppressing melatonin (Lack and Wright 2007).  This has important implications for circadian 
entrainment to the external environment.  For example, the spectral composition of twilight 
(dawn or dusk) differs from that of daylight, having enriched shorter wavelength light (<500nm).  
The detection of such a difference of wavelength at the beginning and end of the day could be an 
important cue for the entrainment of the circadian system (Roenneberg and Foster 1997).   
Similarly, the circadian resetting response to light varies depending on the timing of light 
exposure.  A phase response curve (PRC) can show how induced phase changes can vary across 
the day (Roenneberg and Foster 1997).  The degree and direction of phase shifting varies 
depending on where the stimulus is given in relationship to circadian phase.  A study in 1991 
found that bright light (~5000-9000 lux) given before CBT minimum produces a phase delay, 
while light exposure after CBT minimum produces a phase advance.  The greatest phase shifts 
were found for light given within two hours of the CBT minimum, suggesting that the window 
surrounding body temperature minimum is the period most susceptible to phase shifting by light 
(Minors, Waterhouse et al. 1991).  However, it has been found that light exposure throughout the 
day contributes to circadian entrainment (Duffy and Wright 2005).   
The intensity of light exposure can also affect the degree of phase shifting.  Light 
intensity is measured in lux, which is based on the sensitivity of the human visual system to light 
(Duffy and Wright 2005). While it is well established that bright light (for example, 10,000 lux) 
shifts the circadian clock, it has been found that dim light ~100 lux exposure could produce 
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nearly half the effect seen by 10,000 lux exposure (Zeitzer, Dijk et al. 2000).  It has also been 
demonstrated that light as low as ~1.5 lux (about equivalent to very dim candle light) was 
sufficient to maintain entrainment to a 24 hour day but not sufficient to entrain to longer or 
shorter days (Wright, Hughes et al. 2001). 
Delayed and advanced sleep phase syndrome 
Two types of insomnia, early morning awakening and sleep onset insomnia, have been 
shown to be associated with changes in melatonin and CBT rhythms. Early morning awakening 
insomniacs express advanced rhythms and sleep onset insomnias express delayed rhythms 
(Morris, Lack et al. 1990; Lack, Mercer et al. 1996; Shibui, Uchiyama et al. 1999).  Furthermore, 
these types of insomnia have been successfully treated with light therapy and melatonin (Lack 
and Wright 2007).  In two studies of evening bright light administration (2500 lux for 4 hours) 
among early morning awakening insomniacs, CBT and dim light melatonin were significantly 
phase delayed by around 2 hours (Lack and Wright 1993; Lack, Wright et al. 2005).  In both of 
these studies, TST increased and subjective ratings of sleep improved.  Melatonin has also been 
used successfully as a treatment for elderly insomniacs (Haimov, Lavie et al. 1995; Zhdanova, 
Wurtman et al. 2001).  This evidence strongly suggests an underlying circadian component to 
these types of insomnia, such as advanced or delayed sleep phase syndrome.  In advanced and 
delayed sleep phase syndromes there is an inappropriate phase relationship between biological 
time and environmental time, which results in sleep occurring at a socially acceptable but 
biologically inappropriate time (Duffy and Wright 2005).  Optimally, sleep is initiated ~5 hours 
before the CBT minimum and waking occurs at ~2-3 hours after the CBT minimum.  In 
normally entrained sleepers, this occurs across the period of environmental darkness, for 
example between 23:00 and 7:00.  Surrounding the window for optimal sleep are two zones 
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during which either the circadian or homeostatic component of sleep drive is promoting 
wakefulness, thus making it an inopportune time to sleep.  Individuals who attempt sleep during 
these windows report difficulty sleeping and poor sleep quality (Lack and Wright 2007).  For 
example, if an individual’s circadian rhythm is delayed, the individual would have difficulty 
initiating sleep at an appropriate clock time, as their CBT does not begin to decline until much 
later.   
The associations between CBT, melatonin, and sleep/wake activity are well-known, but 
how these factors interact is still being explored.  It is known that sleep is facilitated by the loss 
of heat through distal body sites such as the hands and feet and it is suspected that melatonin 
plays a key role in CBT regulation through peripheral heat loss (Krauchi, Cajochen et al. 1999; 
Markwald, Lee-Chiong et al. 2010).   Sleepiness is correlated with increasing melatonin levels 
and decreasing body temperature.  It is hypothesized that decreasing CBT signals the 
ventrilateral pre-optic area (VLPO) of the hypothalamus (a primary sleep-promoting area of the 
brain) to initiate sleep (Krauchi, Cajochen et al. 2006).   Skin on the palms of the hands has been 
shown to have an increase in blood flow with a dose of exogenous melatonin, which further 
strengthens the evidence that melatonin may contribute to heat loss through peripheral 
vasodilation (Aoki, Zhao et al. 2008).    
Similar to melatonin, it is proposed that ramelteon works partly through modulation of 
core body temperature via distal vasodilation to promote heat loss at the hands and feet 
(Markwald, Lee-Chiong et al. 2010).  Ramelteon reaches peak serum levels of 5,700 pg/mL 
within 30-90 minutes of administration, but has a half-life 1-2 hours longer than that of 
melatonin (Karim, Tolbert et al. 2006).  This effect is compounded by the presence of 
ramelteon’s M-II metabolite, which remains in circulation an additional 2-5 hours longer than 
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ramelteon.  Although M-II has a lower potency than ramelteon, it reaches much higher 
concentrations in the blood and therefore results in 20-100% greater systemic exposure (Karim, 
Tolbert et al. 2006; Pandi-Perumal, Srinivasan et al. 2007).  Ramelteon has no rebound or 
withdrawal effects and does not alter sleep architecture like hypotic drugs do, which results in a 
more natural night’s sleep according to EEG parameters (Roth, Stubbs et al. 2005; Erman, 
Seiden et al. 2006).  Ramelteon has also been shown to produce phase advances in humans when 
administered in the evening, which makes it an optimal candidate for treating some of the 
chronobiological underpinnings of insomnia (Richardson, Zee et al. 2008). 
 
CURRENT STUDY 
Aims, hypotheses 
 
This thesis was conducted as part of a larger collaborative study between Richard 
Bootzin, PhD at the University of Arizona and Kenneth P. Wright, PhD, University of Colorado 
at Boulder to assess sleep, daytime functioning, and circadian phase effects of a selective 
melatonin receptor agonist (ramelteon) combined and separately with multi-component 
behavioral therapy in patients with chronic insomnia.  The secondary aim of this study, from 
which this thesis project was derived, was to determine if a change in sleep/wake circadian phase 
was associated with treatment efficacy.  It was hypothesized that both ramelteon and MCBT will 
be more effective than placebo at post-treatment and that the combined ramelteon/MCBT 
treatment will be more effective than either treatment alone.   We also expected that SOL would 
be related to phase angle and that the change in phase angle pre to post treatment would correlate 
with improvement in treatment efficacy as measured by decreased SOL and increased TST. 
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Methods 
Participants had to meet the standard criteria of primary insomnia, reporting a SOL of 
more than 30 minutes on at least 3 nights a week and average TST less than 6.5 hours.  
Participants underwent physical and mental health screening including a physical exam, 
interviews about medical and sleep/wake histories, and alcohol, drug, and caffeine use.  
Participants with a diagnosis or treatment of other sleep disorders including obstructive sleep 
apnea, narcolepsy, and period limb movement disorders were excluded from the study, as were 
subjects who had received treatment for insomnia in the past 6 months.  Other exclusion criteria 
were having a history of drug or alcohol abuse or dependency, psychiatric disorders, shift work 
or travel across more than three time zones within 6 months of the study. 
For two weeks prior to the study, subjects’ sleep-wake activity was monitored using 
actigraphy and with sleep diaries in which subjects reported bed and wake times in addition to 
SOL, WASO, number of awakenings, SQ, TIB, TST, and subjective ratings on the quality of 
sleep.  Subjects were scored for sleep quality using the Pittsburgh Sleep Quality Index (PSQI)10.  
Subjects also completed a baseline DLMO assessment in the laboratory.  Throughout the 6 week 
study subjects lived at home.  Subjects in the MCBT treatment group received four weekly 90-
minute group sessions and either 8mg of ramelteon daily or placebo.  The remaining subjects 
received 8mg ramelteon or placebo with no therapy component.  Ramelteon or placebo was 
taken in the evening, approximately 30-60 minutes prior to bedtime.  Sleep and wake activity 
were measured with sleep diaries for two weeks pre-, during, and post-treatment.   
During the pre- and post-treatment saliva collection, wakefulness light exposure 
remained <25 lux maximum anywhere in the room.  Saliva samples were collected with salisaver 
                                                
10 The PSQI is a questionnaire that calculates subjective sleep quality and self-reported sleep disturbances into an 
overall score of sleep quality.  A score of ≤5 is associated with good sleep quality, while a score >5 indicates poor 
sleep quality. 
18 
 
ALPCO Inc. saliva collection devices every 60 minutes during pre- and post-treatment visits.   
Frozen samples were shipped to the University of Colorado at Boulder, where they were assayed 
for melatonin content using a high sensitivity ALPCO ELISA with a detection range of .3pg/mL-
25pg/mL.  DLMO was assessed using a threshold of 3pg/mL.  Change in the phase angle of 
entrainment between melatonin onset and sleep time for pre- and post-treatment were examined. 
Our treatment outcome measures were sleep quality on the PSQI, and SOL and TST based on 
sleep diaries.  Data were analyzed using repeated measures ANOVA with group as a between 
subject factor (placebo, ramelteon and combined MCBT/ramelteon) by pre post treatment as a 
within subject factor.   
Results 
Figure 3 shows the relationship between SOL and phase angle.  Consistent with our 
expectations, the degree of sleep onset disturbance was associated with phase angle such that 
subjects who went to be too close to their melatonin onset showed a longer time to fall asleep. 
  Figure 3.  The relationship between phase angle and SOL before treatment.  
DLMO is marked with a dashed line at 0.  The longer after DLMO subjects 
attempted sleep, the shorter perceived SOL. 
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We found a statistically significant (p<.05) difference in phase angle between pre- and 
post-treatment nights in the ramelteon condition but not in the combined treatment or placebo 
conditions (Table 1).  No association was found between the change in phase angle and treatment 
efficacy for SOL (r=0.09, p=ns) or TST (r=0.04, p=ns).  
Table 1.  Phase angle changes between baseline and week 6 
Baseline 2.18 ± 0.47 Placebo Week 6 2.17 ± 0.73 
Baseline 2.94 ± 0.62 Ramelteon Week 6* 1.44 ± 0.96 
Baseline 2.82 ± 0.39 MCBT+ramelteon Week 6 2.59 ± 0.61 
*significant change from baseline (p<.05) 
 
A main effect of pre post treatment was observed for SOL, WASO, number of 
awakenings, SQ, TST, and sleep efficiency.  
For most of the sleep outcome measures we did not find a significant difference between 
groups.  The number of awakenings decreased significantly in the placebo and combined 
treatment groups, but not in the ramelteon-only condition.  SQ was significantly increased in the 
combined group condition, and TST was significantly increased in the placebo condition.  These 
results are summarized in Table 2. 
   
Table	  2.	   Placebo	  (n=7)	   Ramelteon	  (n=7)	   MCBT+ramelteon	  (n=12)	  
Parameter	   Baseline	  
Post	  
Treatment	   P	   Baseline	  
Post	  
Treatment	   P	   Baseline	  
Post	  
Treatment	   P	  
SOL	  (min)	   50.4	  ±	  10.6	   32.9	  ±	  8.3	   <	  .05	   60.1	  ±	  10.6	   38.3	  ±	  8.3	   <	  .05	   51.3	  ±	  8.1	   26	  ±	  6.4	   <	  .001	  
Number	  of	  
Awakenings	  
1.9	  ±	  .4	   1.1	  ±	  .4	   <	  .05	   2.1	  ±	  .4	   1.8	  ±	  .4	   0.329	   2.2	  ±	  .3	   1.3	  ±	  .3	   <	  .001	  
WASO	  (min)	   31.7	  ±	  8.6	   16.7	  ±	  4.2	   0.066	   18.1	  ±	  8.6	   12.6	  ±	  4.2	   0.481	   47.6	  ±	  6.5	   16.9	  ±	  3.2	   <	  .001	  
Sleep	  Quality	   2.6	  ±	  .1	   2.9	  ±	  .2	   0.180	   2.9	  ±	  .1	   3.0	  ±	  .2	   0.709	   2.7	  ±	  .1	   3.1	  ±	  .1	   <	  .05	  
TIB	  (min)	   474.1	  ±	  27.3	   513.7	  ±	  28.7	   0.272	   464.7	  ±	  27.3	   479.4	  ±	  28.7	   0.679	   493.7	  ±	  20.8	   444.2	  ±	  21.9	   0.078	  
TST	  (min)	   349.9	  ±	  27.8	   432.9	  ±	  25.3	   <	  .05	   344.6	  ±	  27.8	   391.9	  ±	  25.3	   0.116	   351.3	  ±	  21.2	   391.7	  ±	  19.3	   0.081	  
SE	  (%)	   74	  ±	  4	   85	  ±	  3	   <	  .05	   74	  ±	  4	   82	  ±	  3	   <	  .05	   71	  ±	  3	   88	  ±	  2	   <	  .001	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  We found a significant improvement in PSQI scores for all groups in post-treatment and 
follow-up compared to baseline.  These data are shown in Figure 4.  Furthermore, 50% of the 
subjects in the MCBT-ramelteon condition improved their PSQI scores to ≤5 for the post-
treatment and follow-up evaluations; whereas zero subjects in the placebo and ramelteon only 
conditions improved their PSQI scores to ≤5 for the post-treatment evaluation and zero in the 
placebo condition and only one out of five subjects in the ramelteon condition showed a PSQI ≤5 
for the follow-up evaluation.  A PSQI score of ≤5 is considered to be good sleep quality, so these 
subjects could be considered to be effectively treated for insomnia.  
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Figure	  4.	  	  This	  ﬁgure	  shows	  the	  change	  in	  PSQI	  scores	  from	  baseline	  (BL)	  to	  the	  post-­‐
treatment	  (post)	  assessment	  at	  week	  6,	  and	  a	  follow-­‐up	  (FU)	  assessment	  a]er	  the	  study.	  	  
Signiﬁcant	  improvements	  were	  found	  in	  all	  groups	  between	  the	  baseline	  assessment	  and	  
the	  post-­‐treatement	  and	  follow-­‐up	  assessments.	  
*	  diﬀerent	  from	  baseline	  (p<.05)	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Discussion  
Findings from the current study show for the first time a significant correlation between 
phase angle and SOL in patients with insomnia.   The larger the phase angle, the greater the 
distance between DLMO and bedtime, with negative numbers indicating bedtime occurring 
before DLMO.  In this population, all but one subject went to bed after melatonin onset, and 
those who attempted sleep closer to or before melatonin onset had longer sleep latencies.  This 
indicates that some of these insomniacs could be attempting to fall asleep at biological time 
when the circadian clock is promoting wakefulness; that is, subjects may be going to bed too 
early.  
Phase angle, as described previously, was calculated by measuring the difference in 
average bedtime from the time of DLMO.  Insomniacs can have incredibly variable bedtimes 
from day to day, as was evidenced in the sleep diaries – some showing subjects going to bed as 
much as 6 hours later on one night than the previous night.  Although most subjects kept fairly 
consistent bedtimes (±2hrs) throughout the treatment period, the subjects who deviated further 
could have skewed the post-treatment phase angle calculation.   
We found that ramelteon significantly changed phase angle.  The sample size was too 
small to determine whether the degree of change in phase angle was associated with the degree 
of sleep improvement.   
All treatments and placebo groups significantly reduced sleep onset latency, reduced the 
number of awakenings and increased sleep efficiency. Placebo also significantly increased TST. 
Such findings are typical in other insomnia studies, with subjects in the placebo group showing 
improvements when participating in research studies.   The combination of MCBT and ramelteon 
also significantly reduced WASO and improved sleep quality.   
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All groups showed improved sleep quality on the PSQI, but only the combined treatment 
group showed subjects who achieved a level of improvement to ≤5 which an in indication of 
remission of insomnia.   
Limitations of the current study:   
The primary limitation in this study is the small sample size within groups.  Due to drop-
outs and missing data for some subjects, there was limited post treatment data for some groups.  
Due to incomplete post treatment data, we were only able to calculate the change in phase angle 
for 21 subjects – 4 in the ramelteon only group, 10 in the combined therapy group, and 7 in the 
placebo condition.  Thus a study with a larger completed sample size may be necessary to 
examine whether a change in phase angle in the combined MCBT and ramelteon groups would 
be associated with improved sleep.    It is also possible that not all of these subjects had an 
underlying circadian component to their insomnia.  
Another factor that influences phase angle is changes in light exposure between the pre- 
and post-treatment visits.    For example, a subject who has to get up early for work each day will 
be more likely to be exposed to the short-wavelength “twilight” exposure that appears to be a 
stronger signal for entrainment than normal daylight (Roenneberg and Foster 1997).  An 
individual who rises in the late morning or early afternoon may miss this important 
environmental cue for appropriate synchronization of internal and external time.  Also, as 
subjects were not restricted to laboratory-controlled light conditions, they may have 
inadvertently phase-delayed themselves through exposure to light during the 2 hour window 
before CBT minimum where the clock is more sensitive to phase delay as was described 
previously. 
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Conclusions and directions for future research 
 Although we did not see the hypothesized effect that change in phase angle would be 
correlated with treatment efficacy, we did find results that are promising for future research.  The 
correlation between phase angle and sleep onset latency should be validated in a larger 
population of insomniacs, and more work should be done to explore how phase angle relates to 
subjective sleep quality in patients with insomnia.  A follow-up study with a similar design but 
more subjects may be able to show a significant relationship between phase angle and treatment 
efficacy and might be able to show a more robust relationship between phase angle and SOL; 
especially using objective outcome measures   The implications of this finding are important for 
the treatment of insomnia, as it highlights the importance of attempting to sleep at an appropriate 
biological time.  As more evidence arises that implicates circadian misalignment as an 
underlying cause of insomnia, better treatment strategies can be developed like the combinations 
of light, melatonin agonists and cognitive behavioral therapy that are more likely to address 
underlying mechanisms of insomnia and result in a more effective and more sustained 
improvement in sleep quality.
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APPENDIX: 
 
Multi-component behavioral therapy 
MCBT integrates stimulus control instructions, sleep restriction therapy, sleep education, and 
cognitive therapy to help address many of the complex issues contributing to insomnia and poor 
sleep quality. 
Stimulus Control 
Stimulus control is a form of conditioning that helps strengthen cues for sleep and weaken cues 
for activities and behaviors that are incompatible with sleep.   Stimulus control attempts to curb 
behaviors like watching television and reading in the bedroom, and attempts to retrain 
individuals to the bedroom as a place for sleep instead of a place for worrying, planning, or 
eating (Bootzin and Nicassio 1978). 
Sleep Restriction Therapy 
Sleep restriction therapy helps insomniacs improve sleep efficiency by limiting the amount of 
time they spend laying in bed.  
Sleep Education 
Sleep education gives people a basic understanding of sleep and factors that promote, interrupt, 
or otherwise affect it.  For example, this education might involve information about the effects of 
alcohol, caffeine, daytime naps, or exercise on sleep. 
Cognitive Therapy 
Cognitive therapy addresses irrational beliefs about sleep held by insomniacs and helps promote 
more constructive attitudes and beliefs through providing accurate information and realistic 
expectations. 
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